In this article, we will be taking a look at the 7 Hot Healthcare Stocks to Buy Right Now. ResMed Inc. is placed fourth among them. ResMed Inc. (NYSE:RMD) is a leading health technology company focused on sleep, breathing, and home care solutions. The company develops innovative devices and digital platforms that support patients with sleep apnea, chronic respiratory conditions, and related disorders, combining medical expertise with advanced technology to improve patient outcomes globally. In 2025, ResM ...

Core Insights - The importance of sleep is increasingly recognized as a critical pillar of human health alongside diet and exercise [1] - The World Sleep Congress highlights the relationship between sleep, health, and wellness, as well as the prevalence of sleep disorders, particularly insomnia, which affects over 70% of people in Asia [2] Company Insights - ResMed is a key player in the sleep apnea market, primarily generating revenue from CPAP (Continuous Positive Airway Pressure) machines, which are considered the gold standard for treating sleep apnea [3][5] - ResMed is also involved in alternative therapies for sleep apnea, including mandibular devices and nerve stimulation, but emphasizes that CPAP is the most effective treatment for the majority of patients [6][7] Product Developments - Modern CPAP machines have evolved to be smaller, quieter, and more comfortable, with cloud connectivity that enhances patient adherence to therapy [9][10] - Studies indicate that patients using cloud-connected CPAP machines have a significantly higher adherence rate of over 70%, which can increase to over 85% when patients actively engage with their therapy data through an app [10][11] Health Implications - Untreated sleep apnea is linked to increased mortality rates, with a 35% increase in overall mortality and a 55% increase in cardiovascular mortality [11][12] - The condition exacerbates various health issues, including cardiovascular disease, hypertension, and even dementia, highlighting the critical need for awareness and treatment [12]

Core Insights - Resmed has launched the Sleep Institute, a global clinical insights initiative aimed at advancing the science and understanding of sleep health [1][2][3] Group 1: Initiative Overview - The Sleep Institute partners with clinicians, researchers, policymakers, and health system leaders to provide evidence-based insights that inform care innovation and elevate sleep as a global health priority [2][3] - The initiative aims to address the significant underdiagnosis of sleep disorders, particularly obstructive sleep apnea (OSA), which affects an estimated 1 billion people globally [3][5] Group 2: Research and Findings - A U.S. consumer survey revealed that while over 80% of respondents consider sleep important for their health, only one-third have been asked about their sleep by a healthcare professional in the past six months, highlighting a gap in routine healthcare discussions [4][6] - The Sleep Institute will publish original research and real-world data to support earlier and more accurate diagnoses of sleep disorders [3][4] Group 3: Symposium and Collaboration - The Sleep Institute will debut at the World Sleep Congress with a symposium focused on the underdiagnosis of OSA, featuring clinical leaders from various countries [5][6] - The symposium aims to identify barriers in diagnostic pathways and propose scalable solutions to improve access and outcomes in sleep health [5][6] Group 4: Goals and Vision - The overarching goal of the Sleep Institute is to act as a catalyst for earlier diagnosis, stronger policies, and improved outcomes in sleep health worldwide [6][8] - Resmed envisions a future where better sleep and breathing can help individuals achieve their full potential, with care delivered in their homes [9]

Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized careSAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in The Lancet Respiratory Medicine projecting a significant rise in obstructive sleep apn ...

Albert Anthony is the pen name of a Croatian-American business author who is a media contributor on investor platform Seeking Alpha, where he has over +1K followers, & also writes for platforms like Investing dot com and is launching a book on Amazon in 2025 called Real Estate Investment Trusts (REITs): A Fundamental Analysis.The author comes from a non-traditional financial background having been an analyst in the IT sector for several Fortune 500 companies in the US, as well as the technical support team ...

Milestones underscore Resmed's leadership and commitment to delivering life-changing health technology that people love SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its AirTouch™ N30i nasal cradle mask won two prestigious Red Dot Awards: Product Design 2025 in both the Innovative Products and Medical Design & Healthcare categories. The AirTouch N30i features R ...

Core Insights - Resmed has elected Nicole Mowad-Nassar to its board of directors, effective August 15, 2025, while thanking Rich Sulpizio for his two decades of service as he retires from the board [1][5]. Group 1: Board Changes - Nicole Mowad-Nassar is currently the President of Specialty and U.S. Therapeutics Operations at AbbVie, managing a $6 billion commercial portfolio across 17 therapeutic areas and overseeing a workforce of 6,000 [2]. - Rich Sulpizio has served on Resmed's board since 2005, chairing the Compensation Committee and serving on the Audit Committee and Nominating and Governance Committee [5][6]. - Mowad-Nassar will serve as an independent director and has been appointed to the Compensation and Leadership Development Committee, standing for reelection at the 2025 Annual Meeting of Stockholders [4]. Group 2: Professional Background - Mowad-Nassar has over 30 years of experience in strategic, commercial, and operational roles within the pharmaceutical and healthcare sectors, with a focus on digital innovation [7]. - At AbbVie, she played a key role in the commercial integration of the $63 billion Allergan acquisition, ensuring continuity in product launches while minimizing operational disruption [3]. Group 3: Leadership Perspectives - Mick Farrell, Resmed's Chairman and CEO, highlighted Mowad-Nassar's extensive experience and commitment to patient access and digital engagement, indicating her potential to enhance the board's strategic direction [4]. - Farrell expressed gratitude for Sulpizio's contributions, noting his energy and people-first mindset during board discussions [6].

Part I [Item 1. Business](index=4&type=section&id=Item%201.%20Business) ResMed is a global leader in digital health and cloud-connected medical devices for sleep apnea, COPD, and residential care software, operating in over 140 countries [General Overview and Corporate History](index=4&type=section&id=General%20Overview%20and%20Corporate%20History) ResMed, founded in 1989, is a global leader in digital health and cloud-connected medical devices for sleep and breathing health, recently acquiring VirtuOx - ResMed is a **global leader** in **digital health** and **cloud-connected medical devices** for treating **sleep apnea, COPD**, and other chronic diseases, with a focus on **out-of-hospital care**[14](index=14&type=chunk) - The company operates in **two segments**: **Sleep and Breathing Health** and **Residential Care Software**[25](index=25&type=chunk) - In **May 2025**, ResMed **acquired VirtuOx**, a **software-enabled independent diagnostic testing facility (IDTF)**, to strengthen its position in **home-based diagnostics** and **patient monitoring**[19](index=19&type=chunk) [The Market](index=5&type=section&id=The%20Market) ResMed targets underpenetrated global markets for sleep apnea (over 936 million affected), COPD (480 million), and residential care software - A 2019 study estimated that mild to severe Obstructive Sleep Apnea (OSA) impacts more than **936 million people worldwide**, with over **424 million** having moderate to severe cases; diagnosis rates remain low, estimated at less than **20% in the U.S.** and **10% or less in other markets**[30](index=30&type=chunk) - A 2022 study published in CHEST found that consistent PAP therapy use increased survival chances for sleep apnea patients by **39% over a three-year period** compared to untreated patients[32](index=32&type=chunk) - Chronic Obstructive Pulmonary Disease (COPD) is the world's **third leading cause of death** and is estimated to affect approximately **480 million people globally**[43](index=43&type=chunk) - The **Residential Care Software business** targets providers in **home medical equipment (HME), home infusion, home health, hospice, skilled nursing facilities, and senior living communities**, helping them manage operational and compliance complexities[50](index=50&type=chunk) [Business Strategy](index=10&type=section&id=Business%20Strategy) ResMed's strategy focuses on differentiating sleep apnea products, accelerating market growth, expanding into adjacent health, investing in digital health, and aligning residential care software - Grow and differentiate the core sleep apnea portfolio by integrating **AI/ML** and simplifying diagnostic pathways, as demonstrated by the **acquisition of VirtuOx**[55](index=55&type=chunk) - Accelerate market growth by increasing awareness of **sleep apnea and COPD** among the general population, medical specialists, and special interest groups[55](index=55&type=chunk) - Leverage its installed base of over **30 million cloud-connected devices** on AirView and **10 million patients** on myAir to enable personalized and data-driven care[57](index=57&type=chunk) - Utilize Residential Care Software solutions to drive **revenue synergies and interoperability**, supporting over **160 million individual patient accounts**[57](index=57&type=chunk) [Products](index=11&type=section&id=Products) ResMed's product portfolio comprises Devices (52% of FY2025 revenue), Mask Systems (36%), and Residential Care Software (12%) for sleep, respiratory, and out-of-hospital care Revenue by Product Category (FY2023-2025) | Product Category | FY2025 Revenue % | FY2024 Revenue % | FY2023 Revenue % | | :--- | :--- | :--- | :--- | | Devices | 52% | 52% | 54% | | Masks, diagnostics, accessories | 36% | 35% | 34% | | Residential Care Software | 12% | 12% | 12% | [Sales, Manufacturing, and Reimbursement](index=14&type=section&id=Sales%2C%20Manufacturing%2C%20and%20Reimbursement) ResMed markets globally, operates a worldwide manufacturing network facing supply constraints, and relies on third-party reimbursement subject to healthcare reforms - The company markets products in over **140 countries** through a network of distributors and direct sales staff, with tailored approaches for different geographies[79](index=79&type=chunk) - ResMed operates a globally distributed manufacturing network with main facilities in **Singapore, Australia, California, Malaysia, and Georgia** to optimize quality, cost, and supply chain resilience[86](index=86&type=chunk)[90](index=90&type=chunk) - The supply chain is subject to disruptions and constraints for electronic components like **semiconductor chips and magnets**; changes in trade policy, such as **tariffs**, also pose inflation risks[87](index=87&type=chunk)[88](index=88&type=chunk) - Business success is highly dependent on **third-party payor reimbursement**, which is subject to cost-containment measures such as the **DMEPOS Competitive Bidding Program** and other healthcare reforms in the U.S. and abroad[91](index=91&type=chunk)[95](index=95&type=chunk) [Competition, IP, and Regulations](index=17&type=section&id=Competition%2C%20IP%2C%20and%20Regulations) ResMed faces intense competition and alternative therapies, protects its technology with 10,000 patents, and is subject to extensive regulations including FDA, MDR, and data privacy laws - Primary competitors in the Sleep and Breathing Health market include **Philips BV, Fisher & Paykel Healthcare**, and several other regional and new-entrant manufacturers[106](index=106&type=chunk) - The company faces competition from alternative therapies, including surgical procedures, dental appliances, and new pharmaceuticals like **GLP-1 weight loss drugs**, which may reduce the severity of OSA[107](index=107&type=chunk) - ResMed relies on a portfolio of approximately **10,000 pending, allowed, or granted patents and designs globally** to protect its proprietary technology[110](index=110&type=chunk) - The company's products are subject to extensive regulation by the **FDA in the U.S.** (typically via 510(k) clearance) and the **European Medical Device Regulation (MDR) in the EEA**, which requires CE marking[112](index=112&type=chunk)[124](index=124&type=chunk) - ResMed must comply with numerous healthcare fraud and abuse laws (e.g., **Anti-Kickback Statute**), data privacy regulations (**HIPAA, GDPR, CCPA**), and emerging laws governing **Artificial Intelligence** (e.g., EU AI Act)[133](index=133&type=chunk)[149](index=149&type=chunk)[160](index=160&type=chunk) [Human Capital](index=26&type=section&id=Human%20Capital) As of June 30, 2025, ResMed employed approximately 10,600 people globally, with a 12% turnover rate, fostering an inclusive, performance-based culture Employee Distribution by Function and Region (as of June 30, 2025) | Category | Number of Employees | Percentage of Total | | :--- | :--- | :--- | | **Total Employees** | **~10,600** | **100%** | | **By Function** | | | | Cost of Sales (Warehousing/Manufacturing) | ~4,240 | 40% | | Research and Development | ~1,990 | 19% | | Sales, Marketing & Administration | ~4,370 | 41% | | **By Region** | | | | U.S., Canada & Latin America | ~3,250 | 31% | | Asia | ~3,250 | 31% | | Europe | ~2,530 | 24% | | Australia | ~1,570 | 14% | - The average global employee turnover rate for fiscal year 2025 was approximately **12%**[168](index=168&type=chunk) - The company supports **nineteen employee-driven Employee Resource Groups (ERGs)** to foster community and inclusion[170](index=170&type=chunk) [Item 1A. Risk Factors](index=30&type=section&id=Item%201A.%20Risk%20Factors) ResMed faces significant risks from intense competition, alternative therapies, macroeconomic conditions, supply chain disruptions, cybersecurity, and evolving regulatory and reimbursement policies - Competition from new technologies, including pharmaceuticals like **GLP-1s for weight loss**, could reduce the severity or existence of OSA, potentially making the company's products noncompetitive[193](index=193&type=chunk) - Global macroeconomic conditions, including **inflation, supply chain disruptions** (e.g., for rare earth materials from China), and **tariffs**, could adversely affect operations and profitability[196](index=196&type=chunk)[225](index=225&type=chunk) - The company is increasingly dependent on IT systems and is vulnerable to **cybersecurity threats**, including **AI-driven attacks**, which could lead to data breaches, business disruption, and legal liability under regulations like **HIPAA and GDPR**[227](index=227&type=chunk)[228](index=228&type=chunk)[230](index=230&type=chunk) - Healthcare reform, cost-cutting measures, and changes in reimbursement policies by payors like **Medicare** (e.g., competitive bidding) may negatively impact sales and pricing[255](index=255&type=chunk)[266](index=266&type=chunk) - The **acquisition of VirtuOx** subjects ResMed to new areas of direct healthcare oversight, including compliance with rules for Medicare-enrolled suppliers and heightened risk under fraud and abuse laws[221](index=221&type=chunk) [Item 1C. Cybersecurity](index=54&type=section&id=Item%201C.%20Cybersecurity) ResMed manages cybersecurity risks through a NIST and ISO 27001-aligned program, overseen by the Board and CISO, with no material incidents reported to date - The cybersecurity program is aligned with standard industry frameworks such as **NIST and ISO 27001** and is integrated into the overall enterprise risk management program[327](index=327&type=chunk)[328](index=328&type=chunk) - The Board of Directors oversees cybersecurity risk management, receiving at least **annual updates from the Chief Information Security Officer (CISO)**[333](index=333&type=chunk) - The **CISO**, who has over **20 years of experience**, manages a team responsible for day-to-day threat management and incident response[335](index=335&type=chunk)[336](index=336&type=chunk) - The company is not aware of any past cybersecurity threats or incidents that have materially affected or are reasonably likely to materially affect its business, operations, or financial condition[332](index=332&type=chunk) [Item 2. Properties](index=55&type=section&id=Item%202.%20Properties) ResMed operates global properties, including owned executive offices in San Diego and manufacturing in Sydney, with other key facilities across the U.S., Asia, and Europe Principal Properties (as of June 30, 2025) | Location | Ownership | Square Footage | Primary Usage | | :--- | :--- | :--- | :--- | | San Diego, CA | Owned | 230,000 | Corporate HQ, R&D, Sales | | Sydney, Australia | Owned | 437,000 | Manufacturing, R&D, Sales | | Suzhou, China | Owned | 53,000 | Manufacturing, Warehouse, R&D | | Atlanta, GA | Leased | 467,000 | Manufacturing, Warehouse | | Singapore | Leased | 305,000 | Manufacturing, R&D, Sales | | Johor, Malaysia | Leased | 284,000 | Manufacturing, R&D | [Item 3. Legal Proceedings](index=56&type=section&id=Item%203.%20Legal%20Proceedings) ResMed is involved in ordinary course legal proceedings, including patent infringement cases with NYU and Cleveland Medical Devices, with no material adverse financial impact expected - The company is defending against a patent infringement lawsuit from **New York University (NYU)** regarding its AutoSet/AutoRamp features; the **PTAB has invalidated the challenged claims**, and the case is stayed pending NYU's appeal[610](index=610&type=chunk) - ResMed is also involved in patent infringement litigation with **Cleveland Medical Devices Inc.** concerning its connected devices and data platforms; these cases are in various stages, with some proceedings stayed pending PTAB reviews[611](index=611&type=chunk)[614](index=614&type=chunk) Part II [Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=57&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) ResMed's common stock trades on NYSE (RMD), with 10.8 million shares remaining for repurchase and $100.0 million in repurchases during Q4 FY2025 - During the three months ended June 30, 2025, the company repurchased **418,734 shares** of its common stock at an average price of **$238.81 per share**[346](index=346&type=chunk) - As of June 30, 2025, **10.8 million shares** can still be repurchased under the company's approved share repurchase program[346](index=346&type=chunk) [Item 6. Selected Financial Data](index=58&type=section&id=Item%206.%20Selected%20Financial%20Data) ResMed showed consistent five-year growth, with net revenue increasing from **$3.20 billion to $5.15 billion** and net income from **$474.5 million to $1.40 billion** by FY2025 Selected Financial Data (2021-2025) | (In millions, except per share data) | 2025 | 2024 | 2023 | 2022 | 2021 | | :--- | :--- | :--- | :--- | :--- | :--- | | **Net revenue** | $5,146.3 | $4,685.3 | $4,223.0 | $3,578.1 | $3,196.8 | | **Gross profit** | $3,055.0 | $2,655.3 | $2,355.7 | $2,024.3 | $1,839.1 | | **Income from operations** | $1,685.4 | $1,319.9 | $1,131.9 | $1,000.3 | $903.7 | | **Net income** | $1,400.7 | $1,021.0 | $897.6 | $779.4 | $474.5 | | **Diluted earnings per share** | $9.51 | $6.92 | $6.09 | $5.30 | $3.24 | | **Total assets** | $8,174.4 | $6,872.4 | $6,751.7 | $5,095.9 | $4,728.1 | | **Total stockholders' equity** | $5,967.9 | $4,864.0 | $4,129.9 | $3,360.8 | $2,885.7 | [Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=60&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) In FY2025, ResMed's net revenue grew **10% to $5.15 billion**, gross margin improved to **59.4%**, and net income reached **$1.40 billion**, supported by strong liquidity [Results of Operations (FY2025 vs. FY2024)](index=61&type=section&id=Results%20of%20Operations%20(FY2025%20vs.%20FY2024)) In FY2025, net revenue grew **10% to $5.15 billion**, gross margin expanded to **59.4%**, and net income significantly increased to **$1.40 billion**, driven by segment growth and efficiencies Net Revenue by Segment and Product (FY2025 vs. FY2024) | (In millions) | FY 2025 | FY 2024 | % Change | | :--- | :--- | :--- | :--- | | **Total Net Revenue** | **$5,146.3** | **$4,685.3** | **10%** | | **Sleep and Breathing Health** | $4,504.9 | $4,101.2 | 10% | | - Devices | $2,665.2 | $2,444.0 | 9% | | - Masks and other | $1,839.7 | $1,657.2 | 11% | | **Residential Care Software** | $641.4 | $584.1 | 10% | - Gross margin increased to **59.4% in FY2025** from **56.7% in FY2024**, primarily due to procurement, manufacturing, and logistics efficiencies, as well as lower expenses related to field safety notifications for masks with magnets and Astral devices[376](index=376&type=chunk) - Net income for FY2025 was **$1,400.7 million ($9.51 per diluted share)**, a significant increase from **$1,021.0 million ($6.92 per diluted share) in FY2024**[390](index=390&type=chunk) - The effective income tax rate decreased to **16.5% in FY2025** from **19.3% in FY2024**, primarily due to an IRS refund of interest and penalties and tax benefits from the cessation of certain business activities[386](index=386&type=chunk) [Liquidity and Capital Resources](index=66&type=section&id=Liquidity%20and%20Capital%20Resources) ResMed's liquidity strengthened in FY2025, with cash and equivalents rising to **$1.21 billion**, operating cash flow at **$1.75 billion**, and a fully available **$1.5 billion** credit facility Cash Flow Summary (FY2025 vs. FY2024) | (In millions) | FY 2025 | FY 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $1,751.6 | $1,401.3 | | Net cash used in investing activities | ($200.0) | ($269.8) | | Net cash used in financing activities | ($606.3) | ($1,119.3) | | **Net increase in cash** | **$971.1** | **$10.5** | - As of June 30, 2025, the company had cash and cash equivalents of **$1,209.5 million** and total debt of **$670.0 million**[397](index=397&type=chunk)[405](index=405&type=chunk) - The company had full availability of its **$1,500.0 million revolving credit facility** as of June 30, 2025[398](index=398&type=chunk)[403](index=403&type=chunk) - During FY2025, ResMed paid **$310.9 million in dividends ($2.12 per share)** and repurchased **$300.0 million of treasury stock**[410](index=410&type=chunk)[411](index=411&type=chunk) [Item 7A. Quantitative and Qualitative Disclosures About Market and Business Risks](index=72&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20and%20Business%20Risks) ResMed faces market risks from foreign currency, interest rates, and inflation, mitigating currency exposure with a hedging program totaling **$2.54 billion** notional value - The company has significant foreign currency exposure from its manufacturing in **Australia and Singapore** and its international sales operations[434](index=434&type=chunk) - ResMed uses a foreign currency hedging program, including **cross-currency swaps, options, and forward contracts**, to manage exposures mainly in **Euros, Australian dollars, and Singapore dollars**[435](index=435&type=chunk)[439](index=439&type=chunk) - As of June 30, 2025, the notional value of outstanding foreign cross-currency swaps (designated hedges) was **$1.13 billion**, and non-designated hedges was **$1.41 billion**[438](index=438&type=chunk)[440](index=440&type=chunk) - The company is exposed to interest rate risk on its **$1.21 billion in cash and cash equivalents** and **$170.0 million in variable-rate debt**; a **10% change in rates** in FY2025 would not have been material[446](index=446&type=chunk) [Item 8. Consolidated Financial Statements and Supplementary Data](index=75&type=section&id=Item%208.%20Consolidated%20Financial%20Statements%20and%20Supplementary%20Data) This section presents ResMed's audited consolidated financial statements for FY2025, including notes and KPMG LLP's unqualified opinion on financials and internal controls [Consolidated Financial Statements](index=78&type=section&id=Consolidated%20Financial%20Statements) For FY2025, ResMed reported strong financial health with total assets at **$8.17 billion**, net revenue of **$5.15 billion**, and net income of **$1.40 billion** Key Financial Statement Figures (FY2025) | Metric | Amount (in billions) | | :--- | :--- | | Total Assets | $8.17 | | Total Liabilities | $2.21 | | Total Stockholders' Equity | $5.97 | | Net Revenue | $5.15 | | Net Income | $1.40 | | Diluted EPS | $9.51 | | Net Cash from Operations | $1.75 | [Notes to Consolidated Financial Statements](index=83&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) The notes detail accounting policies, revenue recognition, goodwill (**$3.05 billion**), total debt (**$668.3 million**), stock-based compensation (**$91.7 million** expense), and segment operating profits for FY2025 - The goodwill balance was **$3.05 billion** as of June 30, 2025, primarily split between the Residential Care Software (**$2.16 billion**) and Sleep and Breathing Health (**$0.88 billion**) segments; no impairment was recorded during the year[534](index=534&type=chunk) - Total debt as of June 30, 2025, was **$668.3 million**, consisting of a term loan, senior notes, and other short-term debt[542](index=542&type=chunk) - The company recognized **$91.7 million in stock-based compensation costs in FY2025**; as of June 30, 2025, **11.9 million shares** remained available for future issuance under the 2009 Incentive Award Plan[566](index=566&type=chunk)[580](index=580&type=chunk) Segment Net Operating Profit (FY2025) | Segment | Net Operating Profit (in millions) | | :--- | :--- | | Sleep and Breathing Health | $1,964.4 | | Residential Care Software | $205.0 | | **Total** | **$2,169.4** | [Item 9A. Controls and Procedures](index=110&type=section&id=Item%209A.%20Controls%20and%20Procedures) As of June 30, 2025, management and KPMG LLP concluded that ResMed's disclosure controls and internal control over financial reporting were effective - The CEO and CFO concluded that the company's disclosure controls and procedures were **effective** as of June 30, 2025[636](index=636&type=chunk) - Management concluded that the company's internal control over financial reporting was **effective** as of June 30, 2025, based on the COSO framework[643](index=643&type=chunk) - KPMG LLP issued an **unqualified opinion** on the effectiveness of the company's internal control over financial reporting as of June 30, 2025[646](index=646&type=chunk) [Item 9B. Other Information](index=113&type=section&id=Item%209B.%20Other%20Information) No Rule 10b5-1 trading arrangements were adopted or terminated in Q4 FY2025, and bylaws were amended on August 6, 2025, regarding stockholder action and board classification - No directors or executive officers adopted or terminated a **Rule 10b5-1 trading plan** in the fourth quarter of fiscal 2025[656](index=656&type=chunk) - On **August 6, 2025**, the company's bylaws were amended to modify certain limitations on stockholder action by written consent and remove references to a classified board[657](index=657&type=chunk) Part III Part III information (Items 10-14) regarding governance, compensation, and security ownership is incorporated by reference from the upcoming definitive proxy statement - Information for **Items 10, 11, 12, 13, and 14** is incorporated by reference from the company's definitive proxy statement[661](index=661&type=chunk)[664](index=664&type=chunk)[665](index=665&type=chunk) Part IV Part IV lists all exhibits filed with the Form 10-K, including corporate governance documents, material contracts, SOX certifications, and Inline XBRL financial data - This section lists all exhibits filed as part of the **Form 10-K report**, including financial statements, schedules, and required certifications[670](index=670&type=chunk)

Resmed Inc RMD reported better-than-expected earnings for the second quarter on Thursday.The company posted quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $2.46 per share. The company reported quarterly sales of $1.348 billion which beat the analyst consensus estimate of $1.321 billion.“Our strong finish to fiscal year 2025 reflects ongoing momentum across our business, driven by robust global demand for our market-leading sleep and breathing health devices, as well as ou ...

Core Insights - Resmed Inc. reported adjusted earnings per share (EPS) of $2.55 for Q4 fiscal 2025, reflecting a 22.6% year-over-year increase and surpassing the Zacks Consensus Estimate by 3.66% [1] - The company's total revenue for Q4 was $1.35 billion, a 10.2% increase year-over-year, also exceeding the Zacks Consensus Estimate by 1.87% [3] - For the full fiscal year, adjusted EPS was $9.55, up 23.7% from fiscal 2024, and slightly above the Zacks Consensus Estimate by 0.5% [2] Revenue Performance - Q4 revenues from the Sleep and Breathing Health segment reached $1.18 billion, a 10.2% increase year-over-year, exceeding projections [5] - Device revenues within this segment were $693.9 million, up 9.3%, with notable growth in the U.S., Canada, and Latin America [5] - The Residential Care Software segment saw revenues grow 9.9% year-over-year to $167 million, aligning with expectations [7] Margin and Cost Analysis - Adjusted gross profit for Q4 was $827.9 million, a 14.4% increase, with an adjusted gross margin of 61.4%, up 227 basis points year-over-year [9] - Adjusted operating income rose 19% to $476.4 million, with an adjusted operating margin expanding 260 basis points to 35.3% [10] Financial Position - At the end of Q4, Resmed had cash and cash equivalents of $1.21 billion, significantly up from $238.4 million at the end of fiscal 2024 [11] - Total debt decreased to $668.3 million from $707.2 million at the end of fiscal 2024 [11] - The company generated cumulative net cash from operating activities of $1.75 billion, compared to $1.40 billion in the previous year [11] Shareholder Returns - In Q4, Resmed paid out $78 million in dividends and repurchased 419,000 shares for $100 million as part of its capital management strategy [12] Strategic Developments - The growth in sales was attributed to strong global demand for sleep and breathing health devices and the expansion of the digital health ecosystem [13] - The acquisition of VirtuOx enhanced Resmed's capabilities in providing at-home diagnostic services, supporting earlier patient care [14] - Improvements in gross margin were driven by efficiencies in procurement, manufacturing, and logistics, along with favorable currency movements [15]